Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


25. August 2020 | 11:56 CET

Bayer, Siltronic, XPhyto - is it worthwhile to invest now?

  • Investoren
Photo credits: pixabay.com

Tuesday began with green lights for most listed companies in Germany. The opinions of analysts and company announcements make the stock prices - or they are driven by the mood of economic data. The Ifo Business Climate Index, for example, rose by 2.2 points to 92.6 points in August 2020 compared to July. The survey data is collected every month from around 9,000 companies and makes it the most important leading indicator in Germany. "The German economy is on course for recovery," Ifo President Clemens Fuest announced. In this context, stocks that still have potential are now exciting.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Study results expected in Q4

XPhyto Therapeutics Corp. this morning announced an update on its transdermal delivery system for the neurological drug Rotigotine. The German subsidiary Vektor Pharma TF GmbH ("Vektor") has completed the process implementation for the manufacture of its Rotigotine patches. The next step will be the production of clinical samples and analytical work in Vector's EU GMP laboratory and manufacturing facility in Baden-Württemberg, Germany. Human bioavailability studies in Europe are planned for Q3 2020 and results are expected in Q4 2020, the company announced.

Rotigotine approved in EU and USA

The active pharmaceutical ingredient Rotigotine can be used for the treatment of Parkinson's disease and restless legs syndrome in Europe and the United States and is approved accordingly. It is a generic and off-patent drug, usually formulated as a once-daily transdermal patch to provide a slow and steady supply of the drug over a 24-hour period.

Focus on commercialization

"Our goal is the commercialization of a low-cost Rotigotine patch with superior bioavailability and adhesion properties," said Hugh Rogers, XPhyto's CEO. "Incorporating Rotigotine into Vektor's novel transdermal drug delivery system platform is a major accomplishment. With the formula locked and manufacturing soon to commence, we look forward to the upcoming clinical studies."

Analysts adjust

At the beginning of the week Bayer had two 'Buy' ratings. The Swiss UBS issued a target price of EUR 110.00, but DZ Bank lowered the fair value of the share from EUR 79.00 to EUR 75.00. The reason for the reduction in the target price was uncertainty about the settlement of future glyphosate litigation. Siltronic's shares are now among the winners on the price lists, as Credit Suisse upgraded the rating from 'Neutral' to 'Outperform' and raised the price target from EUR 90.00 to EUR 100.00.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.